Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News and Analysis
  • Published:

Success of immunomodulators in MS shifts discovery focus to neuroprotection

Nature Reviews Drug Discovery volume 10, pages 885–887 (2011)Cite this article

Subjects

Abstract

With six immunomodulatory agents in late-stage development for relapsing–remitting multiple sclerosis, this area of the therapeutic space has become highly competitive. Could remyelination therapies that provide neuroprotection be the next frontier?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Authors
  1. Asher Mullard
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mullard, A. Success of immunomodulators in MS shifts discovery focus to neuroprotection. Nat Rev Drug Discov 10, 885–887 (2011). https://doi.org/10.1038/nrd3610

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3610

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research